ReviewInternational journal of molecular sciences2021
Emerging Roles of Calcium Signaling in the Development of Non-Alcoholic Fatty Liver Disease.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Mitochondrial NCLX couples glucagon- and PDE2A-Dependent signals to regulate hepatic lipid metabolism.Molecular metabolism · 2026Article
- Mitochondrial Dysfunction in Metabolic-Syndrome-Related MASLD/MASH: Metabolic Mechanisms and Therapeutic Perspectives.Metabolites · 2026Review
- STIM/Orai-Mediated Store-Operated CaCells · 2026Review
- Triglycerides and Hypertension in a Korean Population: An Individual-Level Mendelian Randomization Analysis.Nutrients · 2026Article
- Identification of a Calcium-Related Prognostic Signature and Validation of CACNA1B as a Driver of Metastasis in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Calcium imbalance drives organelle network collapse and immune remodeling: novel pathogenic mechanisms in MASLD progression.Frontiers in immunology · 2026Review
- Elucidating the material basis and therapeutic mechanisms of Shaoma Zhijing granules for tourette syndrome by UPLC/Q-TOF-MS and multiple models.Metabolic brain disease · 2025Article
- Nonfat Milk Supplementation Mitigates Hepatic Lipid Accumulation and Improves Hepatic Lipid Metabolism in an Early Metabolic Dysfunction-Associated Steatotic Liver Disease C57BL/6N Mouse Model.The Journal of nutrition · 2025Article
- Mitochondrial Dysfunction as a Pathogenesis and Therapeutic Strategy for Metabolic-Dysfunction-Associated Steatotic Liver Disease.International journal of molecular sciences · 2025Review
- Microrna363-5p targets thrombospondin3 to regulate pathological cardiac remodeling.Molecular and cellular biochemistry · 2025Article
- Induction of MASH-like pathogenesis in the Nwd1Communications biology · 2025Article
- Impact of static magnetic field exposure onJournal of advanced veterinary and animal research · 2025Article
- Mitochondrial DNA Mutations as a Factor in the Heritability of Atherosclerosis and Other Diseases.Current medicinal chemistry · 2025Review
- Metabolic dysregulation in MASLD-associated HCC: diagnostic biomarkers and therapeutic opportunities.Frontiers in medicine · 2025Review
- Metformin's effect on metabolic dysfunction-associated steatotic liver disease through the miR-200a-5p and AMPK/SERCA2b pathway.Frontiers in pharmacology · 2024Article
- NREP contributes to development of NAFLD by regulating one-carbon metabolism in primary human hepatocytes.Cell chemical biology · 2023Article
- Cross-species analysis of differential transcript usage in humans and chickens with fatty liver disease.Veterinary world · 2023Article
- Alterations in the hepatocyte epigenetic landscape in steatosis.Epigenetics & chromatin · 2023Article
- NAFLD/MAFLD: New Evidence.International journal of molecular sciences · 2023Article
- Aflatoxin BToxins · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The liver plays a central role in energy metabolism. Dysregulated hepatic lipid metabolism is a major cause of non-alcoholic fatty liver disease (NAFLD), a chronic liver disorder closely linked to obesity and insulin resistance. NAFLD is rapidly emerging as a global health problem with currently no approved therapy. While early stages of NAFLD are often considered benign, the disease can progress to an advanced stage that involves chronic inflammation, with increased risk for developing end-stage disease including fibrosis and liver cancer. Hence, there is an urgent need to identify potential pharmacological targets. Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.